Clinical cure · bacterial boils (furuncles and carbuncles)
It is very uncertain whether azithromycin changes clinical cure (measured 7 days after treatment) compared with cefaclor (very low certainty).
1 finding from 1 review
Severe adverse events leading to withdrawal of treatment · bacterial boils (furuncles and carbuncles)
1 finding from 1 review
Quality of life · bacterial boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of folliculitis or boil following completion of treatment · bacterial boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events not leading to withdrawal of treatment · bacterial boils (furuncles and carbuncles)
It is very uncertain whether azithromycin changes minor adverse events not leading to withdrawal of treatment… compared with cefaclor (very low certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with resolution of itch within 2… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo or vitamins (low certainty).
1 finding from 1 review
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Mild abdominal pain. · pityriasis rosea
Azithromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse events and severe adverse events · people with chronic plaque psoriasis
1 finding from 1 review
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · people with chronic plaque psoriasis
It is very uncertain whether azithromycin changes proportion of participants achieving PASI 75 or PGA 1 to 2 compared with vitamin C (very low certainty).
1 finding from 1 review
Relapse · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
It is very uncertain whether azithromycin changes participant‐assessed improvement in rosacea severity compared with doxycycline 100 mg (very low certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
It is very uncertain whether azithromycin changes proportion of participants with adverse event compared with doxycycline 100 mg (very low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review